Blood-Based Prognostic Prediction Model for Glioblastoma: Construction and Validation
Cancer Management and Research · 2025-04 · Volume 17 · 835-850
DOI: 10.2147/cmar.s510217 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Management and Research, 2025-04. Verfasst von Shibo Gao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Objective
Objective: To explore the prognostic factors affecting patients with glioblastoma (GBM) treated with the Stupp regimen and establish a prediction model based on hematological indicators to guide future clinical decision - making.
Methods
A total of 271 GBM patients meeting the screening criteria were recruited. They were randomly divided into a training set (190 cases) and a validation set (81 cases) at a 7:3 ratio. The training set was utilized to establish a comprehensive hematology prognostic scoring system (CHPSS), and the validation set was employed to verify the CHPSS. A Risk Score (RS) was computed from the CHPSS, and a nomogram model was constructed to predict patients' overall survival (OS) based on the RS. Additionally, the relationship between RS and the surgery - to - radiotherapy interval (SRI) was analyzed.
Results
Patients were categorized into low - risk and high - risk groups according to the RS calculated by CHPSS. The overall survival of patients in these two groups differed significantly. The C - indices of the nomogram model constructed based on RS and clinical features were 0.79 and 0.73 in the training and validation sets, respectively. The clinical decision curve showed that when the threshold probability exceeded 20%, the model's prediction provided the greatest net benefit for GBM patients receiving the Stupp regimen. In the overall cohort, a correlation between RS and SRI was observed, allowing for the classification of SRI into different risk subgroups based on RS.
Conclusion
The nomogram model based on CHPSS can effectively evaluate the prognosis of glioblastoma patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Zitieren
APA
Gao, S., Liu, Y., Kong, J., Huangfu, L., Yang, Y., Cui, H., Sun, X., Shi, S., & Yang, D. (2025). Blood-Based Prognostic Prediction Model for Glioblastoma: Construction and Validation. Cancer Management and Research, Volume 17, 835-850. https://doi.org/10.2147/cmar.s510217
Vancouver
Gao S, Liu Y, Kong J, Huangfu L, Yang Y, Cui H, et al. Blood-Based Prognostic Prediction Model for Glioblastoma: Construction and Validation. Cancer Management and Research. 2025;Volume 17:835-850. doi:10.2147/cmar.s510217
BibTeX
@article{Gao2025,
author = {Gao, Shibo and Liu, Yukun and Kong, Jinglin and Huangfu, Linkuan and Yang, Yuchuan and Cui, Haiyang and Sun, Xiaocong and Shi, Shuling and Yang, Daoke},
title = {Blood-Based Prognostic Prediction Model for Glioblastoma: Construction and Validation},
journal = {Cancer Management and Research},
year = {2025},
volume = {Volume 17},
pages = {835--850},
doi = {10.2147/cmar.s510217}
}
EUVIMED